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Malignancy is the second most common cause of mortality in the reproductive period and it
complicates up to one out of every 1000 pregnancies. When cancer is diagnosed during preg-
nancy, the management approach must take into consideration both the mother and her fetus.
Hematologic cancers diagnosed in pregnancy are not common, resulting in paucity of random-
ized controlled trials. Diagnosis of such malignancies may be missed or delayed, as their symp-
toms are similar to those encountered during normal pregnancy. Also, many imaging studies
may be hazardous during pregnancy. Management of these malignancies during pregnancy
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Lymphomasinduces many treatment-related risks for mother and baby and should consider patient’s pref-
erences for pregnancy continuation. In this article, hematologic malignancies diagnosed in preg-
nant patients including acute leukemias, chronic myeloid leukemia, lymphomas, multiple
myeloma and myeloproliferative neoplasms, will be reviewed, including diagnostic and manage-
ment strategies and their impact on the pregnant patient and the developing fetus.
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Having malignancy during pregnancy may put the patient and
the treating physician in a very serious situation, as weighing
the risk of cancer versus the lethal effect of the chemotherapy
used for its treatment is a very tough issue. So it is very impor-
tant to address whom, when, and how to treat those patients.
That is to say treating physician should ask himself some ques-
tions. The first is would this type and/or stage of the disease
needs immediate intervention or treatment could be postponed
till delivery. The second question is how can he treat this case
during pregnancy using the safest road to reach a safe place,
meaning that which type of chemotherapy would the mother
tolerate and exert no or little side effects on the fetus during
different trimesters of pregnancy.
Incidence
Cancer is diagnosed in approximately one out of 1000 preg-
nant women and this incidence is expected to grow due to
the rising median age at pregnancy. The most common cancers
associated with pregnancy are cervical (1.2:10000 pregnancies),
breast cancer (1:3000–10000), melanoma (2.6:1000), lym-
phomas (1:1000–6000) and leukemias (1:75000–100000).
Hematologic malignancies, which are considered to be diseases
of old age, such as multiple myeloma (MM) and myeloprolif-
erative neoplasms (MPNs), are recently more commonly
encountered while the patients are pregnant owing to the rising
median age at pregnancy, improved diagnostic molecular
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MM. On the other hand myelodysplastic syndrome (MDS),
and chronic lymphocytic leukemia (CLL) generally occur
at an older age, so they are rarely diagnosed during
pregnancy [1].
Diagnosis and staging of cancer during pregnancy
Several procedures are considered safe to be performed during
any stage of pregnancy such as core needle or excisional biop-
sies and bone marrow (BM) biopsy [2].
Computed tomography (CT) scans and positron emission
tomography (PET) scans should not be performed for
staging of lymphoma during pregnancy due to the risk of
radiation exposure of the fetus [3]. Ultrasonography can
be safely used during pregnancy, while plain chest X-ray
(CXR) can be performed, if required, in pregnant women
with adequate abdominal shielding. Magnetic resonance
imaging (MRI) should be avoided in the first trimester of
pregnancy, while it can be performed during second and
third trimesters if it is strongly indicated assuming that its
results would significantly influence the management plan
[4]. Gadolinium (a contrast medium used in MRI) should
not be used in the first trimester, as it crosses the placenta
and causes fetal malformations [5]. Gadolinium MRI scans
can be used during second and third trimesters if strongly
indicated [1].
Isotopic bone scans are generally not recommended during
pregnancy unless there are no other means of detecting bone
metastases and results would alter the treatment strategy. On
the other hand, MRI has a specificity of 91% for the detection
of bone metastases in hematologic cancers [6].
Acute leukemias
Acute leukemia (AL) developing during pregnancy necessitates
amultidisciplinary teammanagement includingamedical oncol-
ogist, an obstetrician, and a neonatologist. It requires immediate
management irrespective of the gestational age as any delayment
in therapy can seriously affect the prognosis of the mother [7].
Recommendations for management of these patients are ham-
pered by the rarity of these conditions in pregnancy and insuffi-
ciency of available data in the literature. The largest experience
of AL in pregnancy came fromMayo Clinic (1962–1999), where
17 cases of AL in pregnancy were treated [8]. Another retrospec-
tive study of 37 AL patients from 13 French centers was per-
formed (1988–2003), in which vincristine, doxorubicin,
daunorubicin, idarubicin, cytarabine, cyclophosphamide,
asparaginase, mercaptopurine, prednisone, methotrexate,
mitoxantrone, and all-trans-retinoic acid (ATRA)have been uti-
lized during all trimesters [9]. In a review of 152 patients with
ALL and AML, six neonates with congenital abnormalities, 12
with intrauterine growth retardation (IUGR), 11 fetal deaths,
and 2 neonatal deaths were recorded [10].
Acute myeloid leukemia (AML)
The majority of cases with AML are diagnosed in the second
or third trimesters. The standard regimen for induction con-
sists of cytarabine and an anthracycline [11].Exposure to cytarabine in the first trimester can cause sev-
ere limb malformations and its use is not advocated and termi-
nation is strongly preferred. In the second and third trimesters,
it was associated with transient cytopenias, intrauterine fetal
death, IUGR, and neonatal death from sepsis and gastroen-
teritis [10]
Daunorubicin is the anthracycline of choice in pregnancy.
Although rare cases of fetal cardiotoxicity have been docu-
mented with anthracycline use, fetal cardiac function should
be monitored during pregnancy [12].
For relapsed AML, termination of pregnancy is highly rec-
ommended, because treatment usually requires high-dose
chemotherapy, and BM transplantation, which cannot be
given safely in pregnancy [13].
In summary, counseling and termination of pregnancy in
first trimester are recommended. In second and third trime-
sters, induction chemotherapy with daunorubicin and cytara-
bine can be introduced, with regular surveillance for the
development of congenital abnormalities and monitoring of
fetal cardiac function.
Acute promyelocytic leukemia (APL)
The hematologic manifestations of APL, such as pancytope-
nia, disseminated intravascular coagulation and hyperfibrinol-
ysis represent a medical emergency during pregnancy. Women
with APL diagnosed during pregnancy have higher risks of
abortion, perinatal mortality, IUGR, and preterm delivery
[9]. Clinical sequelae include increased bleeding, infection,
inflammation, placental abruption, and decreased oxygen
and nutrient delivery [14].
APL is usually treated by ATRA combined with
anthracycline-based chemotherapy (idarubicin or daunoru-
bicin). It has a complete remission rate of >90% and a poten-
tial cure in up to 80%. During pregnancy, this drug regimen is
controversial due to the potential teratogenic effects and
medication-related complications such as fatal retinoic acid
syndrome [15]. Retinoic acid in low doses is especially harmful
to the fetus during weeks 3–5 of gestation. Complications that
can result include craniofacial alterations, neural tube defects,
cardiovascular malformations, and thymic aplasia [16]. How-
ever, the risk of teratogenic effects during the second and third
trimesters of pregnancy is low [17].
In the first trimester, ATRA should be avoided, and women
should be counseled to consider termination. Should termina-
tion of the pregnancy be unacceptable, treatment with an
anthracycline should be started and ATRA introduced in the
second trimester. Daunorubicin is the anthracycline of choice,
not only because there is more experience of its use in preg-
nancy, but also because it may induce less fetal toxicity than
idarubicin. Treatment after the beginning of the second trime-
ster results in a more successful outcome. Chemotherapy does
not appear to cause congenital abnormalities, but undoubtedly
increases the risk of abortion, prematurity, low birth weight,
neonatal neutropenia, and sepsis. Potentially, ATRA could
be given alone with the addition of the anthracycline after
delivery. This has resulted in remission rates equivalent to
combination of ATRA and chemotherapy. However, using
ATRA as a single agent increases the risk of ATRA syndrome
(APL differentiation syndrome) and possible ATRA resis-
tance. Alternatively, use of ATRA and an anthracycline is rec-
592 H.K. Mahmoud et al.ommended for high-risk patients with hyperleukocytosis.
Arsenic trioxide (ATO), which has been used for relapsed
APL patients and more recently explored as first-line therapy,
cannot be recommended at any stage of pregnancy as it is
highly embryotoxic [13,16,17].
Acute lymphoblastic leukemia (ALL)
In a review by Terek et al. [18], 28% of leukemia cases diag-
nosed during pregnancy are ALL. In this study, a total of 17
patients with ALL received chemotherapy between gestational
age of 15 and 33 weeks. Most chemotherapy regimens included
anthracyclines, vincristine and steroids. About half of the
women in this study achieved remission while the other half
either relapsed or died from progression of the disease. Some
infants were born with transient pancytopenia, respiratory dis-
tress and preterm delivery [18].
Before week 20 of gestation, termination should be consid-
ered, and then conventional therapy instituted. After the 20th
week, bridging chemotherapy without methotrexate until the
third trimester can be instituted. A brief period of treatment
with prednisolone alone for 1–2 weeks may allow the patient
to enter the period of gestation post 20 weeks in order to then
receive more intensive chemotherapy. A similar approach with
prednisolone alone can also be recommended for patients pre-
senting close to 32 weeks of pregnancy. Methotrexate, an
important drug in the treatment of ALL, should be avoided
in first and second trimesters of pregnancy and may be used,
if necessary, with caution in the third trimester [13].
Chronic myeloid leukemia (CML)
Recent use of BCR–ABL1 tyrosine kinase inhibitors (TKIs)
has led to marked improvement of survival in CML patients.
Many young female CML patients may become pregnant dur-
ing their lifetime. It is important to mention that TKIs can
inhibit several proteins, which are important for gonadal
development, implantation and fetal development, thus
increasing the risk of toxicities to the embryo. Imatinib is
shown to be embryotoxic in animals with varying effects on
fertility. As pregnancy is rare in CML, there are no random-
ized trials to address the optimal management of this disease.
However, there are several case reports on CML in pregnancy
[19].
Imatinib, the first TKI approved for the treatment of CML,
has revolutionized the results of therapy with complete cytoge-
netic remission and OS rates of 82% and 90% respectively.
However, almost one-third of patients need to be switched to
another line of therapy due to resistance and/or intolerance
to imatinib [20]. Nilotinib, dasatinib, bosutinib and more
recently ponatinib, are safe and efficient drugs for treatment
of patients with chronic phase (CP) CML, who are imatinib
intolerant or resistant [21–23].
As the lifespan of patients responding to different TKIs is
prolonged, many women in reproductive period may seek
medical advice for the possibility of further pregnancy. These
women should be clearly informed about the risks of becoming
pregnant while on therapy and the possibility of a loss of
response after drug discontinuation to continue pregnancy.
However, pregnancy can be planned with sustained optimal
response to TKIs [24].There is limited information about the use of second and
third generation TKIs during pregnancy. Forty-five women
have been reported of nilotinib exposure during pregnancy,
with only one case of fetal abnormalities ending into preg-
nancy termination and another case of fetal death due to con-
genital transposition of great vessels [25]. Dasatinib should be
used with much caution during pregnancy due to more potent
and wider range of signaling pathway inhibition including
platelet-derived growth factor receptor-a [26]. There are no
available data regarding patients receiving bosutinib or pona-
tinib during pregnancy [25].
In a female patient in the childbearing period, effective con-
traception should be suggested at diagnosis. Conception
should be only scheduled after achievement of a sustained
major molecular response (MMR), or a deep molecular
response (e.g. MR4.5) for at least 2 years. TKIs should be dis-
continued just before conception. TKIs should not be used
during the period of fetal organ formation (weeks 5–13 of
pregnancy). Quantitative Polymerase chain reaction (Q-PCR)
tests for BCR/ABL: ABL ratio must be monitored every
1–2 month to assure the sustainability of molecular response.
In case of hematologic or cytogenetic relapse, restarting treat-
ment can be considered. Interferon (IFN) can be used safely
throughout gestation [27]. Hydroxyurea may be considered
to treat leukocytosis after fetal organogenesis [28]. Imatinib
and nilotinib have limited placental transfer and can be used,
if strongly indicated, after formation of placenta [29]. In con-
trast, dasatinib can pass extensively through the placenta,
and it should not be used all through the pregnancy [30].
After labor, TKI therapy can be delayed to permit breast-
feeding, only in case of stable molecular response. If it is
important to restart therapy with TKI, breast milk is recom-
mended during the first few postpartum days to deliver the
colostrum to the baby [25].
Hazards of use of TKIs in pregnancy
Only few case reports of CML patients treated with TKIs dur-
ing pregnancy are published. Most of these patients were trea-
ted with imatinib. In a study of 180 females treated with
imatinib during pregnancy was performed, 50% of the patients
delivered normal infants, and 28% underwent elective termina-
tions (11% of them following identification of abnormalities).
Abnormalities were identified in 12 infants with 9 of those
defects occurring in the infants with known first trimester
exposure to imatinib. In conclusion, most pregnancies exposed
to imatinib are likely to have a successful outcome; however,
there remains a risk that exposure may result in serious fetal
malformations [31].
Fewer cases of exposure to newer TKIs during pregnancy
have been also reported. One case of exposure to nilotinib dur-
ing the first trimester was described in a patient who unexpect-
edly became pregnant while taking nilotinib until 7.4 weeks of
pregnancy. Her baby was delivered without any congenital
anomaly [32]. The outcome of pregnancy in 46 CML patients
who received dasatinib while pregnant was recently reported.
Live births occurred in 20 (43%) patients including 15 healthy
and 5 abnormal infants with IUGR and/or premature delivery.
Termination of pregnancy occurred in 26 (57%) patients
(8 spontaneous and 18 elective). Seven pregnancies resulted
in fetal and infant complications including 2 cases of hydrops
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tract abnormalities [33].
Lymphoma
Staging methods for lymphoma during pregnancy are limited
only to CXR with protective shields for the abdomen, abdomi-
nopelvic US and BM biopsy. BM biopsy is recommended for
patients with lymphoma especially those with systemic (B)
symptoms, and/or peripheral blood cytopenias [34,35]. Labo-
ratory workup should also include complete blood count, ery-
throcyte sedimentation rate, LDH, kidney function and liver
function tests including serum alkaline phosphatase. However,
the latter is highly elevated in the third trimester of pregnancy
and may not be useful [36]. Abdominal disease can be also
evaluated with non-contrast MRI [37,38]. In contrast, PET
and gallium scans are not safe during pregnancy [39].
Non-Hodgkin lymphoma (NHL)
Pregnancy itself may produce symptoms similar to those of
lymphoma leading to a significant delay in diagnosis of such
patients and a higher frequency of advanced disease [40]. Also
in pregnancy-associated NHL, there is a higher frequency of
involvement of reproductive organs due to their increased
blood flow and increased hormone receptor expression during
pregnancy [41]. In a systematic review of pregnant women with
NHL (no = 121), 91 (75%) patients had stage IV disease with
involvement of reproductive organs (mostly the breast) seen in
49% of them [42].
Indolent lymphoma
Due to the nonaggressive nature of indolent lymphomas, their
definitive therapy can be delayed until the second trimester of
pregnancy, or even until delivery. Rituximab monotherapy can
be given safely during the first trimester if there is an urgent
need for treatment. R-CVP regimen (rituximab, cyclophos-
phamide, vincristine and prednisone) or R-CHOP regimen
(R-CVP + doxorubicin) can be used during the second or
third trimester, whereas fludarabine-based regimens are not
recommended [42].
Bendamustine became the standard of care as frontline
therapy in Western world. Bendamustine has been assigned
to pregnancy category D by the US Food and Drug Admira-
tion (FDA). Animal studies have revealed skeletal and visceral
malformations, decreased fetal body weights, a significant
increase in external and internal malformations, as well as
embryo and fetal lethality. There are no controlled data in
human pregnancy. Bendamustine should only be given during
pregnancy when there are no alternatives and benefit out-
weighs risk.
Aggressive lymphomas
Highly aggressive lymphomas (including diffuse large B-cell,
mantle cell and mature T-cell lymphomas) diagnosed in preg-
nancy may be distinguished by an aggressive nature with worse
prognosis due to delay in diagnosis, and insufficient therapy
used. When adequate chemotherapy is given, prognosis ofpregnant patients with NHL is similar to that of non-
pregnant patients [40].
In the majority of patients with aggressive NHL diagnosed,
during pregnancy, early therapy with chemotherapy combina-
tion regimens (such as CHOP) is usually needed. In the first tri-
mester, the safety of CHOP protocol is not guaranteed and
termination of pregnancy is usually advocated [40,43]. In some
NHL patients with stage I/II disease with lower tumor burden,
who are diagnosed in the first trimester, careful follow-up till
the second trimester followed by proper chemoimmunotherapy
may be indicated.
R-CHOP can be given more safely during the second or
third trimester [40,43,44]. In a multicenter study, ninety preg-
nant women with aggressive lymphoma received the standard
chemoimmunotherapy regimens in the second or third trime-
ster of pregnancy with low frequency of maternal and fetal
problems [41].
Highly aggressive lymphomas
As in aggressive lymphomas, the fulminant course and rapid
progression of highly aggressive lymphomas such as lym-
phoblastic and Burkitt’s lymphomas nictitates prompt initia-
tion of aggressive treatment. High-dose methotrexate, which
is usually included in chemotherapeutic regimens for these
lymphomas, is highly toxic to the embryo if used in first trime-
ster. Thus, pregnancy termination is strongly advocated in
such cases [45].
Although methotrexate use during the second and third tri-
mesters may not be teratogenic, it is found to be associated
with severe fetal myelosuppression [40].
Rituximab during pregnancy
Many case reports of rituximab use during pregnancy have
been published, mainly for benign diseases and they did not
show a higher risk of teratogenicity [46,47]. Use of rituximab
for treatment of lymphoma in early pregnancy, may lead to
a temporary fetal B-cells depletion, followed however with
rapid recovery of B-cells [48].
Pregnancy outcomes were reported in a retrospective study
of 153 pregnant patients exposed to rituximab. Live births
were reported in ninety cases and the majority of them were
not complicated. Neonatal complications included transient
leucopenia with or without infections [49].
In conclusion, the beneficial value of rituximab therapy for
aggressive lymphomas during the second or third trimester of
gestation is greater than its hazards to the fetus. In the first tri-
mester, rituximab use cannot be recommended, although the
data on teratogenicity are limited.
Hodgkin lymphoma (HL)
ABVD regimen (doxorubicin, bleomycin, vinblastine and
dacarbazine), the commonest chemotherapy regimen used for
HL, should not be used during the first trimester, as informa-
tion with respect to its safety is restricted. There are no avail-
able safety data regarding the use of other chemotherapeutic
regimens used for treatment of HL such as ‘‘Stanford V” or
‘‘BEACOPP” during pregnancy.
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gestation, should immediately receive chemotherapy with ter-
mination of pregnancy. Early-stage HL diagnosed in the first
trimester could be closely observed for development of disease
progression and begin chemotherapy in the second trimester.
In some cases in first trimester, localized radiotherapy to cervi-
cal and/or axillary area with abdominal shielding is an option
of therapy of HL [34,38,40,50].
Most pregnant women diagnosed with HL during the sec-
ond and third trimesters can be managed with ABVD. In some
cases diagnosed with localized stage (IA or IIA) disease in the
late second or third trimester, chemotherapy can be postponed
until after delivery allowing complete staging and selection of
the proper therapy after labor. However, there are no random-
ized controlled trials comparing the results of early versus
deferred therapy in such patients [38].
The 20-year survival rate of pregnant women with HL was
similar to that of matched non-pregnant women with HL. In
addition, the incidence of preterm delivery or IUGR was not
higher in pregnant women with HL [51].Multiple Myeloma (MM)
Pregnant patients diagnosed with symptomatic MM need
prompt therapy. Immunomodulatory drugs such as thalido-
mide and lenalidomide may induce marked teratogenicity,
and should be avoided during the whole pregnancy period
[52]. Also, bortezomib cannot be recommended in pregnant
patients, as there are few data about its safety.
Corticosteroids are the safest therapy of MM during preg-
nancy, and can be used as a monotherapy in patients with
mildly symptomatic disease until delivery. In rapidly progres-
sive disease, an intensive combination therapy is usually
required. If this progressive disease is diagnosed in the first tri-
mester, termination of pregnancy is recommended. If the
patient has an extensive pelvic or vertebral bone disease,
Cesarean section is preferred to avoid trauma resulting from
vaginal delivery [14].
Ph-negative myeloproliferative neoplasms (MPNs)
Only limited data are available about polycythemia vera (PV)
and essential thrombocythemia (ET) developing during preg-
nancy [53]. In these patients, there is an increased incidence
of abortion (twice as normal), IUGR, and intrauterine death.
Maternal complications occur in about 8% of patients [54,55].
Several factors may influence the therapeutic decision for
PV/ET including disease-related and pregnancy-related fea-
tures. High-risk pregnancy is defined by presence of any of
the following factors: previous thrombosis/hemorrhage in the
mother, previous pregnancy-related complications attributable
to PV/ET, severe preeclampsia, abruptio placentae, and unex-
plained recurrent first trimester fetal loss, IUGR, intrauterine
death [54]. The plasma volume starts to increase from the sec-
ond trimester onward leading to reduction of hematocrit (Hct)
and platelet count; then, these levels start to rise again after
delivery leading to an increased thrombotic risk. Close moni-
toring by weekly blood counts is important during the first
six weeks postpartum to detect rebound thrombocytosis or
polycythemia [55].In PV, it is recommended to maintain the Hct within the
normal range of the contemporary trimester of pregnancy. In
ET, low dose aspirin is safe and beneficial during pregnancy.
In the absence of obvious contraindications, all PV and ET
patients should receive aspirin 75 mg daily throughout gesta-
tion. From the day of delivery, aspirin is replaced by low
molecular weight heparin (LMWH), for 6 weeks [55].
In high-risk pregnancy, LMWH is recommended through-
out pregnancy and 6 weeks after labor. Cytoreductive therapy
is indicated when the platelet level rises above >1000–
1500  109/l or when cardiovascular risk factors are present.
Hydroxyurea and anagrelide should be avoided due to their
teratogenic effects. The drug of choice is non-pegylated IFN,
as it has no teratogenic effects in animals or adverse effects
in the small numbers of patients who receive this drug during
pregnancy. Pegylated forms of IFN (PEG-IFN) are potentially
less safe during pregnancy, as animal studies showed an
adverse effect on the fetus while there are no adequate well-
controlled studies in humans (pregnancy category C). So,
PEG-IFN should be used only when benefit to the mother out-
weighs risk to their fetus. Breast-feeding is safe with LMWH,
but contraindicated with all cytoreductive agents including
IFN [56].
Conclusions
The prognosis of most pregnant women with hematologic
malignancies is similar to that of matched nonpregnant
women. Treatment strategy should put into consideration the
severity of malignancy, the teratogenicity of available effective
drugs and the necessity to continue pregnancy. During the first
trimester, if chemotherapy is necessary, termination of preg-
nancy is generally indicated. The outcome of patients who
receive chemotherapy in the second or third trimester is usually
good.
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